Clinical Trials Search
Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) of VX15/2503 administered in combination with avelumab.
Primary Objective (Dose Escalation Phase): 1. To evaluate the safety and tolerability of ascending doses of VX15/2503 Q2W in combination with avelumab 10mg/kg Q2W. The primary safety endpoint is the number of subjects with dose-limiting toxicities (DLT)s during the 21-day DLT evaluation period at each dose level. Primary Objective (Dose Expansion Phase): 2. To evaluate safety and tolerability of RP2D of VX15/2503 administered in combination with 10 mg/kg avelumab Q2W